KYVERNA THERAPEUTICS, INC. COMMON STOCK
NASDAQ: KYTX (Kyverna Therapeutics, Inc.)
Last update: 2 days ago, 10:15PM8.21
0.09 (1.11%)
| Previous Close | 8.12 |
| Open | 8.00 |
| Volume | 433,473 |
| Avg. Volume (3M) | 1,485,936 |
| Market Cap | 489,370,208 |
| Price / Book | 2.85 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2026 |
| Diluted EPS (TTM) | -3.24 |
| Total Debt/Equity (MRQ) | 3.10% |
| Current Ratio (MRQ) | 7.44 |
| Operating Cash Flow (TTM) | -133.64 M |
| Levered Free Cash Flow (TTM) | -80.19 M |
| Return on Assets (TTM) | -31.08% |
| Return on Equity (TTM) | -49.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Kyverna Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.50 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 12.04% |
| % Held by Institutions | 68.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Gordonmd Global Investments Lp | 31 Dec 2025 | 4,391,818 |
| Insight Holdings Group, Llc | 31 Dec 2025 | 989,054 |
| Propel Bio Management, Llc | 31 Dec 2025 | 666,666 |
| Mbb Public Markets I Llc | 31 Dec 2025 | 614,477 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Wells Fargo, 301.95%) | Buy |
| Median | 29.00 (253.23%) | |
| Low | 25.00 (Morgan Stanley, 204.51%) | Buy |
| Average | 29.00 (253.23%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 16 Dec 2025 | 33.00 (301.95%) | Buy | 10.24 |
| Morgan Stanley | 04 Dec 2025 | 25.00 (204.51%) | Buy | 7.84 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer |
| 12 Jan 2026 | Announcement | Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Announcement | Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference |
| 17 Dec 2025 | Announcement | Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock |
| 15 Dec 2025 | Announcement | Kyverna Therapeutics Announces Proposed Public Offering of Common Stock |
| 15 Dec 2025 | Announcement | Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome |
| 14 Dec 2025 | Announcement | Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |